ArticleInternational journal of hypertension2013
Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study.
Article in International journal of hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 57 citations in OpenAlex.
- The Influence of the Sympathetic Nervous System on Cardiometabolic Health in Response to Weight Gain or Weight Loss.Metabolites · 2025Review
- Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications.Cardiovascular diabetology · 2021Review
- Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.International journal of molecular sciences · 2021Review
- Development of insulin resistance in Nischarin mutant female mice.International journal of obesity (2005) · 2019Article
- Sympathetic nervous system in age-related cardiovascular dysfunction: Pathophysiology and therapeutic perspective.The international journal of biochemistry & cell biology · 2019Review
- Autonomic Regulation of Glucose Homeostasis: a Specific Role for Sympathetic Nervous System Activation.Current diabetes reports · 2018Review
- Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome-A Randomized Controlled Trial.Frontiers in physiology · 2018Article
- The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension.Current hypertension reports · 2017Review
- The Role of the Autonomic Nervous System in the Pathophysiology of Obesity.Frontiers in physiology · 2017Review
- Anti-Inflammatory Effects and Prediction of Blood Pressure Response by Baseline Inflammatory State in Catheter-Based Renal Denervation.Journal of clinical hypertension (Greenwich, Conn.) · 2016Article
- Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?Current hypertension reports · 2016Review
- Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome.Journal of diabetes research · 2015Review
- Antihypertensive drugs and glucose metabolism.World journal of cardiology · 2014Review
- Clinical Practice Guidelines. Management of Hypertension in Tunisian Adults.La Tunisie medicaleArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to assess the effects of moxonidine on blood pressure and aspects of the metabolic syndrome in racially diverse population of patients encountered in routine medical practice. Physicians collected data on a minimum of three consecutive patients with uncontrolled essential hypertension and criteria for metabolic syndrome, eligible to receive moxonidine (0.2-0.4 mg once daily) for 6 months, either as monotherapy or as adjunct therapy to current antihypertensive treatment. Systolic and diastolic blood pressure (BP) declined by an average of 24.5 + 14.3 mmHg and 12.6 + 9.1 mmHg, respectively. BP responder rates defined as attaining BP < 140/90 mmHg were significantly (P < 0.001) and substantially higher among younger patients, nonpostmenopausal women, and patients receiving monotherapy. While potentially relevant improvements in the entire cohort were observed in regard to body weight (-2.1 ± 5.4 kg), fasting plasma glucose (from 6.8 to 6.2 mmol/L), and triglycerides (2.4 to 2.0 mmol/L), statistically significant changes in metabolic parameters could only be detected in subgroup analyses. Moxonidine therapy reduced blood pressure and improved rates of blood pressure control in this group of patients. While the observed trend towards improvement in various metabolic parameters merits further investigation, the overall effect of moxonidine treatment is consistent with a reduction of total cardiovascular risk in this hypertensive metabolic syndrome cohort.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.